Pelabresib,Ruxolitinib
morphosys,constellation pharmaceuticals
['mpnsm', '#mpn']
the og #mpnlegend presenting 1l manifest data (pelabresib + rux) with 68% svr35 and 57%tss50 and good data in add on cohort. manifest 2 phase iii accruing #eha22 #mpnsm 
Executive Director- Mays Cancer Center at UT Health San Antonio MD Anderson. Focus- MPNs #MPNSM, Cancer, Health Equity, QoL (Twitter posts = personal opinion)